Episode Details

New evidence from JAMA Network Open suggesting that switching direct oral anticoagulants after breakthrough ischemic stroke in atrial fibrillation does not improve short-term outcomes; NEJM data from the Beamion LUNG-1 trial showing promising first-line efficacy of zongertinib in HER2-mutant NSCLC; and 10-year follow-up from the FIDELITY trial reinforcing that arthroscopic partial meniscectomy offers no benefit over sham surgery for degenerative meniscal tears and may worsen osteoarthritis progression. Together, these findings may influence future standards in stroke prevention, targeted lung cancer therapy, and orthopedic surgical decision-making.